Assessment of herbal weight loss supplement counseling provided to patients by pharmacists and nonpharmacists in community settings

Journal of the American Pharmacists Association

Volumn 51, Issue 4, 2011, Pages 499-509

  Jordan, Melanie A ^a   Foster, Katherine ^b   Gandhi, Anshu ^c   Mohebbi, Negin ^d   Tehrani, Leila ^e  

^a MIDWESTERN UNIVERSITY   (United States)

^b Good Samaritan Regional Medical Center   (United States)

^c JOHN PETER SMITH HOSPITAL   (United States)

^d CVS Caremark   (United States)

^e ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Dietary supplements; Herbal products; Patient counseling; Weight loss

Indexed keywords

MANNAN;

ARTICLE; BREAST FEEDING; CAMELLIA SINENSIS; CARDIOTOXICITY; DESCRIPTIVE RESEARCH; DIET SUPPLEMENTATION; DIURESIS; EXPLORATORY RESEARCH; FENNEL; GARCINIA CAMBOGIA; GASTROINTESTINAL SYMPTOM; GINGER; GINSENG; GLYCYRRHIZA; GUARANA; HEADACHE; HEALTH CARE PERSONNEL; HEALTH FOOD; HUMAN; HYPERTENSION; HYPOKALEMIA; INSOMNIA; MULTICENTER STUDY; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SAFETY; PHARMACIST; PHARMACY TECHNICIAN; PREGNANCY; RESTLESSNESS; RHABDOMYOLYSIS; SEIZURE; SLEEP DISORDER; SOUR ORANGE; TACHYCARDIA; WEIGHT REDUCTION; WILLOW; COUNSELING; DRUG EFFECT; MEDICINAL PLANT; METHODOLOGY; PHARMACY; PHYTOTHERAPY;

COMMUNITY PHARMACY SERVICES; COUNSELING; DIETARY SUPPLEMENTS; HUMANS; PHARMACISTS; PHYTOTHERAPY; PLANTS, MEDICINAL; WEIGHT LOSS;

EID: 84855170433     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2011.09233     Document Type: Article

References (93)

1. Centers for Disease Control and Prevention, National Center for Health Statistics. 1999-2002 National Health and Nutrition Examination Survey. Washington, DC: Government Printing Office; 2004.
2. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549-55.
3. Kruger J, Galuska DA, Serdula MK, et al. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med. 2004;26:402-6.
4. National Institutes of Health. Dietary Supplement Health and Education Act of 1994. Accessed at http://ods.od.nih.gov/about/dshea-wording.aspx, May 24, 2011.
5. Food and Drug Administration. Dietary supplement enforcement report. Washington, DC: Government Printing Office; 2002.
6. 21 CFR 111; 2007.
7. Food and Drug Administration. Dietary Supplement and Nonprescription Drug Consumer Protection Act. Accessed at www.fda.gov/RegulatoryInformation/ Legislation/FederalFoodDrugandCosmeticActFDCAct/ SignificantAmendmentstotheFDCAct/ucm148035.htm, May 24, 2011.
8. Jellin JM (Ed.). Natural medicines comprehensive database [database online]. Accessed at www.naturaldatabase.com, December 15, 2008.
9. Glisson JK, Rogers HE, Abourashed EA, et al. Clinic at the health food store? Employee recommendations and product analysis. Pharmacotherapy. 2003;23:64-72.
10. Sarino LV, Dang KH, Dianat N, et al. Drug interaction between oral contraceptives and St. John's wort: appropriateness of advice received from community pharmacists and health food store clerks. J Am Pharm Assoc. 2007;47:42-7.
11. Accreditation Council for Pharmacy Education. Accreditation standards and guidelines for the professional program in pharmacy leading to the Doctor of Pharmacy degree. Chicago: Accreditation Council for Pharmacy Education; 2006.
12. O'Donnell DC, Brown CM, Dastani HB. Barriers to counseling patients with obesity: a study of Texas community pharmacists. J Am Pharm Assoc. 2006;46:465-71.
13. Miller LG, Hume A, Harris IM, et al. White paper on herbal products: American College of Clinical Pharmacy. Pharmacotherapy. 2000;20:877-91.
14. Brown CM, Barner JC, Shah S. Community pharmacists' actions when patients use complementary and alternative therapies with medications. J Am Pharm Assoc. 2005;45:41-7.
15. Arizona Administrative Code R4-23-612.
16. Kwan D, Hirschkorn K, Boon H. U.S. and Canadian pharmacists' attitudes, knowledge, and professional practice behaviors toward dietary supplements: a systematic review. BMC Complement Altern Med. 2006;6:31-40.
17. Boon H. CAM and pharmacists: challenge or opportunity? Focus on Alternative and Complementary Therapies. 2005;10:1-3.
18. Ulbricht C (Ed.). Natural standard: the authority of integrative medicine [database online]. Accessed at www.naturalstandard.com, December 15, 2008.
19. Jee SH, He J, Whelton PK, et al. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension. 1999;33:647-52.
20. Backman JT, Karjalainen MJ, Neuvonen M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006;62:345-57.
21. Djordjevic N, Ghotbi R, Bertilsson L, et al. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol. 2008;64:381-5.
22. Michaud V, Mouksassi MS, Labbe L, et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit. 2006;28:779-83.
23. Cheng TO. Green tea may inhibit warfarin. Int J Cardiol. 2007;115:236.
24. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. 1999;33:426-8.
25. Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls. Am J Gastroenterol. 1990;85:1339-42.
26. Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. Ann Pharmacother. 2002;36:992-5.
27. Rapuri PB, Gallagher JC, Kinyamu HK, et al. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr. 2001;74:694-700.
28. Balat O, Balat A, Ugur MG, et al. The effect of smoking and caffeine on the fetus and placenta in pregnancy. Clin Exp Obstet Gynecol. 2003;30:57-9.
29. Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology. 2001;64:51-78.
30. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. Ann Pharmacother. 2004;38:812-6.
31. Haller CA, Benowitz NL, Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med. 2005;118:998-1003.
32. Hess AM, Sullivan DL. Potential for toxicity with use of bitter orange extract and guarana for weight loss. Ann Pharmacother. 2005;39:574-5.
33. Marcus DM, Grollman AP. Ephedra-free is not danger-free. Science. 2003;301:1669-71.
34. Malhotra S, Bailey DG, Paine MF, et al. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69:14-23.
35. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′- dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther. 1999;65:237-44.
36. Penzak SR, Acosta EP, Turner M, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol. 2002;42:1165-70.
37. Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. Ann Pharmacother. 2006;40:53-7.
38. Penzak SR, Jann MW, Cold JA, et al. Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol. 2001;41:1059-63.
39. Bouchard NC, Howland MA, Greller HA, et al. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc. 2005;80:541-5.
40. Yonei Y, Takahashi Y, Hibino S, et al. Effects on the human body of a dietary supplement containing l-carnitine and Garcinia cambogia extract: a study using double-blind tests. J Clin Biochem Nutr. 2008;42:89-103.
41. Hayamizu K, Hirakawa H, Oikawa D, et al. Effect of Garcinia cambogia extract on serum leptin and insulin in mice. Fitoterapia. 2003;74:267-73.
42. Asghar M, Monjok E, Kouamou G, et al. Super CitriMax (HCA-SX) attenuates increases in oxidative stress, inflammation, insulin resistance, and body weight in developing obese Zucker rats. Mol Cell Biochem. 2007;304:93-9.
43. Mansi IA, Huang J. Rhabdomyolysis in response to weight-loss herbal medicine. Am J Med Sci. 2004;327:356-7.
44. Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger (Zingiber officinale roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr. 1996;50:772-4.
45. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. 2006;46:1370-8.
46. Kruth P, Brosi E, Fux R, et al. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother. 2004;38:257-60.
47. Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med. 2004;71:651-6.
48. Willetts KE, Ekangaki A, Eden JA. Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2003;43:139-44.
49. Borrelli F, Capasso R, Aviello G, et al. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol. 2005;105:849-56.
50. Chittumma P, Kaewkiattikun K, Wiriyasiriwach B. Comparison of the effectiveness of ginger and vitamin B6 for treatment of nausea and vomiting in early pregnancy: a randomized double-blind controlled trial. J Med Assoc Thai. 2007;90:15-20.
51. Marcus DM, Snodgrass WR. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol. 2005;106:640.
52. Sripramote M, Lekhyananda N. A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. J Med Assoc Thai. 2003;86:846-53.
53. Vutyavanich T, Kraisarin T, Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. Obstet Gynecol. 2001;97:577-82.
54. Wilkinson JM. Effect of ginger tea on the fetal development of Sprague-Dawley rats. Reprod Toxicol. 2000;14:507-12.
55. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol. 1987;7:201-2.
56. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997;54:692-3.
57. Lee SH, Ahn YM, Ahn SY, et al. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med. 2008;14:715-21.
58. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002;25:323-44.
59. Scaglione F, Cattaneo G, Alessandria M, et al. Efficacy and safety of the standardised ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold. Drugs Exp Clin Res. 1996;22:65-72.
60. Siegel RK. Ginseng abuse syndrome: problems with the panacea. JAMA. 1979;241:1614-5.
61. Chan LY, Chiu PY, Lau TK. An in-vitro study of ginsenoside Rb1-induced teratogenicity using a whole rat embryo culture model. Hum Reprod. 2003;18:2166-8.
62. Chan LY, Chiu PY, Lau TK. Embryotoxicity study of ginsenoside Rc and Re in in vitro rat whole embryo culture. Reprod Toxicol. 2004;19:131-4.
63. Liu P, Xu Y, Yin H, et al. Developmental toxicity research of ginsenoside Rb1 using a whole mouse embryo culture model. Birth Defects Res B Dev Reprod Toxicol. 2005;74:207-9.
64. Koren G, Randor S, Martin S, et al. Maternal ginseng use associated with neonatal androgenization. JAMA. 1990;264:2866.
65. Zhu M, Wong PY, Li RC. Effect of oral administration of fennel (Foeniculum vulgare) on ciprofloxacin absorption and disposition in the rat. J Pharm Pharmacol. 1999;51:1391-6.
66. Burkhard PR, Burkhardt K, Haenggeli CA, et al. Plant-induced seizures: reappearance of an old problem. J Neurol. 1999;246:667-70.
67. Schwartz HJ, Jones RT, Rojas AR, et al. Occupational allergic rhinoconjunctivitis and asthma due to fennel seed. Ann Allergy Asthma Immunol. 1997;78:37-40.
68. Stager J, Wuthrich B, Johansson SG. Spice allergy in celery-sensitive patients. Allergy. 1991;46:475-8.
69. Henry DA, Mitchell AS, Aylward J, et al. Glucomannan and risk of oesophageal obstruction. Br Med J (Clin Res Ed). 1986;292:591-2.
70. Vanderbeek PB, Fasano C, O'Malley G, et al. Esophageal obstruction from a hygroscopic pharmacobezoar containing glucomannan. Clin Toxicol (Phila) 2007;45:80-2.
71. Doi K, Matsuura M, Kawara A, et al. Influence of dietary fiber (konjac mannan) on absorption of vitamin B12 and vitamin E. Tohoku J Exp Med. 1983;141(suppl):677-81.
72. Shima K, Tanaka A, Ikegami H, et al. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res 1983;15:1-3.
73. Chen HL, Sheu WH, Tai TS, et al. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects: a randomized double-blind trial. J Am Coll Nutr. 2003;22:36-42.
74. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002;58:487-90.
75. Yoshida M, Sawa J, Hozumi T, et al. Effects of long-term high-fiber diet on macrovascular changes and lipid and glucose levels in STZ-induced diabetic SD rats. Diabetes Res Clin Pract. 1991;13:147-52.
76. Doi K, Matsuura M, Kawara A, et al. Treatment of diabetes with glucomannan (konjac mannan). Lancet. 1979;1:987-8.
77. Signorelli P, Croce P, Dedè A. A clinical study of the use of a combination of glucomannan with lactulose in the constipation of pregnancy [article in Italian]. Minerva Ginecol. 1996;48:577-82.
78. Tsukamoto S, Aburatani M, Yoshida T, et al. CYP3A4 inhibitors isolated from licorice. Biol Pharm Bull. 2005;28:2000-2.
79. Francini-Pesenti F, Puato M, Piccoli A, et al. Liquorice-induced hypokalaemia and water retention in the absence of hypertension. Phytother Res. 2008;22:563-5.
80. Heikens J, Fliers E, Endert E, et al. Liquorice-induced hypertension: a new understanding of an old disease: case report and brief review. Neth J Med. 1995;47:230-4.
81. Negro A, Rossi E, Regolisti G, et al. Liquorice-induced sodium retention: merely an acquired condition of apparent mineralocorticoid excess? A case report. Ann Ital Med Int. 2000;15:296-300.
82. Strandberg TE, Andersson S, Jarvenpaa AL, et al. Preterm birth and licorice consumption during pregnancy. Am J Epidemiol. 2002;156:803-5.
83. Strandberg TE, Jarvenpaa AL, Vanhanen H, et al. Birth outcome in relation to licorice consumption during pregnancy. Am J Epidemiol. 2001;153:1085-8.
84. Shalansky S, Lynd L, Richardson K, et al. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27:1237-47.
85. Chrubasik S, Kunzel O, Black A, et al. Potential economic impact of using a proprietary willow bark extract in outpatient treatment of low back pain: an open non-randomized study. Phytomedicine. 2001;8:241-51.
86. Krivoy N, Pavlotzky E, Chrubasik S, et al. Effect of salicis cortex extract on human platelet aggregation. Planta Med. 2001;67:209-12.
87. Boullata JI, McDonnell PJ, Oliva CD. Anaphylactic reaction to a dietary supplement containing willow bark. Ann Pharmacother. 2003;37:832-5.
88. Buck ML, Grebe TA, Bond GR. Toxic reaction to salicylate in a newborn infant: similarities to neonatal sepsis. J Pediatr. 1993;122:955-8.
89. Govaert P, Staelens V, Vanhaesebrouch P. Perinatal intracranial hemorrhage due to maternal salicylate ingestion. Clin Pediatr (Phila). 1995;34:174-5.
90. Palatnick W, Tenenbein M. Aspirin poisoning during pregnancy: increased fetal sensitivity. Am J Perinatol. 1998;15:39-41.
91. Unsworth J, d'Assis-Fonseca A, Beswick DT, et al. Serum salicylate levels in a breast fed infant. Ann Rheum Dis. 1987;46:638-9.
92. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-80.
93. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.